Filtered By:
Source: Neurology
Drug: Albuterol
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Safety and Tolerability of Systemic Beta-2-Adrenergic AgonistAlbuterol as Pharmacological Therapy in Non-Invasive Ventilation NIV -supported Amyotrophic Lateral SclerosisALSPatients with Chronic Respiratory Failure (P4.079)
CONCLUSIONS:Systemic albuterol is 94.2% tolerable when used in NIV-supported ALS patients.M NIV-supported ALS patients more commonly required albuterol.VC was maintained at 3 months without change but not at 6 months in albuterol-treated NIV-supported ALS patients.Further studies are required on pharmacologically enhancing the treatment of NIV-supported ALS patients.Study Supported by:Carolinas ALS Research Fund/Pinstripes Fund/Carolinas Garden of Hope/Carolinas Healthcare FoundationDisclosure: Dr. Brooks has received personal compensation for activities with Biogen Idec, Avanir Pharmaceuticals, Acorda Therapeutics, Cytoki...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Brooks, B., Kandinov, B., Langford, V., Lindblom, S., Sanjak, M., Wright, K., Ward, A., Holsten, S., Fischer, M., Lucas, N., Smith, N., Nichols, M., Lary, C., Nemeth, J., Russo, P., Bockenek, W., Bravver, E., Desai, U., Story, J. S., Pacicco, T. Tags: ALS: Trials and Biomarkers Source Type: research
